Author of

• 32024

  +

  EP1.09 - Pathology (ID 199)

  • Event: WCLC 2019
  • Type: E-Poster Viewing in the Exhibit Hall
  • Track: Pathology
  • Presentations: 1
  • Now Available
  • Moderators:
  • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall

  • 32033

    +

    EP1.09-08 - Plasma Circulating Free Tumour DNA in Advanced Lung Adenocarcinoma: EGFR TKI-Naïve (Now Available) (ID 2481)

    08:00 - 18:00  |  Author(s): Setia Putra Tarigan
    • Abstract
    • Slides

    Background
    

    Molecular testing of tumour samples is therefore mandatory in routine clinical practice. Tumour DNA is also present as cell-free molecules in blood, which is therefore a very useful and convenient source of tumour DNA. Circulating tumour DNA (ctDNA) consists of short, double-stranded DNA fragments that are released into the circulation by tumour cell. With the advent of newer molecular platforms, ctDNA can be detected with high sensitivity and specificity in plasma. Aim of this study is to assess diagnostic accuracy of plasma circulating free tumour DNA (ctDNA) in advanced lung adenocarcinoma (EGFR TKI-Naïve) in several hospitals in Medan, Indonesia.

    Method
    

    This was a cross-sectional study whose subjects were patients with adenocarcinoma obtained from histopathology and / or cytology and examined for EGFR mutations from plasma ct-DNA. Data analysis used chi square test and fisher exact test.

    Result
    

    One hundred data have been collected, with male are 71 (71.0%), and 29 are female (29.0%). Found 20 mutations, single mutations from 19 tissue biopsies, del exon 19 as many as 12 cases (60.0%), deletion mutations in Exon 21 (L858R) 6 cases (30.0%), 1 case Exon L861Q (5.0%) and del Exon 19 and 21 L861Q double mutations 1 case (5.0%). From plasma ctDNA examination EGFR mutations were found 15 cases, del Exon 19 : 12 cases (80.0%), del Exon 21 (L858R) 3 cases (20.0%). Plasma ctDNA for detection of EGFR mutations has a sensitivity of 45.0%, specificity of 92.5%. It’s means, all patients with EGFR (+) mutations, ctDNA managed to detect 45% of cases, while 55% of cases detected mutations (-). Then, all patients detected EGFR (+) mutations based on ctDNA, only 60% of cases have EGFR (+) mutations when examined by tissue will be EGFR (-) mutations. The positive predictive value of ctDNA is 60%.

    Conclusion
    

    Plasma ctDNA can be used to detect EGFR mutations but cannot replace tissue biopsy as the gold standard.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.